Laura Testa

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2022 · 566 citations · Full text

Medicine, Endocrinology, Oncology +14

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 493 citations

Medicine, Oncology, Pharmacology +14

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín et al. · Journal of Clinical Oncology · 2024 · 204 citations · Full text

Medicine, Oncology, Pharmacology +15

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17